Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression

NCT04702997 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04702997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
February 9, 2021
Completion date
November 23, 2021
Enrollment
81 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases